Larry Smith, C-Level Executive Email & Phone Number

Washington, Dc, Us

• Founded company offering novel non-dilutive funding structure for biopharmaceutical, medical device and technology firms that is not treated as debt.• Advise startups and early stage companies on corporate structure, strategy, financial and legal infrastructure including recently Solaxa Inc. .• Explore funding opportunities with target companies and collaborate with PE/VC and banks to originate capital.

• Co-founded company developing novel antibodies to treat and prevent COV-19 and other difficult to treat diseases• Structured & negotiated license for strategic assets and collaboration for 5 additional targets with Twist Bioscience Corporation including $10M initial funding commitment• Secure financing from target investors and non-dilutive sources

Billerica, Ma, Us

Senior Vice President, Finance, Global Tax & Treasurer at NASDAQ Listed Company "BRKR"• Built and led high performing tax and treasury teams at Lifescience tools company to improve upon current state• Met with investors and led $1.2B debt raise consisting of 10-year CHF denominated private placement notes, 7-year term debt and 5-year revolver utilizing interest and cross-currency swaps fixing and reducing annual interest by 50%• Revised debt structure to facilitate liquidity, reduce taxes and avoid $16M cash penalty utilizing hedge accounting

Malvern, Pa, Us

• Proactively led global tax function and corporate structure, building lean world-class cross-enterprise team that created competitive advantage and more than $1B of value through novel operating model • Transformed finance into strategic lever developing efficient supply chains to enhance deal value and implemented unique, highly efficient transfer pricing model that delivered $200M annual benefit • Advised investors & reviewed all external releases providing input on critical strategic, M&A, operational, legal, tax, GAAP and non-GAAP reporting issues associated with inverted global Specialty Pharma embroiled in epic mass torts• Trusted advisor participating in business reviews and BOD meetings. Distilled and presented complex value preserving solutions and strategic options to the full BOD at three critical times including creative structure that enabled divestiture generating $1B in incremental cash and the accelerated restructure of the generic business • Lobbied Congress and staff and Ireland Finance to defend and preserve critical structural benefits

Washington, District Of Columbia, Us

• Led global tax function for $60B market-cap company, supporting its rapid global ($8B to $19B in seven years) • Designed multi-prong strategy to support M&A centric, lean decentralized business comprised of 50 BUs to create competitive advantage and reduce tax rate by seven percent• Transformed team from U.S. centric compliance department to proactive, world-class, global, business interfacing team of over 80 spanning nine countries leveraging technology, improving processes and reducing cost• Regularly briefed Risk & Audit Committees (the later included a former IRS Commissioner) • Structured over 120 acquisitions & divestitures saving more than $1B in taxes and enabling $7B in repatriation

• Led tax planning, M&A, in-licensing, transfer pricing, and compensation/benefits responsibilities comprising team of six, reporting directly to VP-Tax, and served as Secretary of FEC (Finance Executive Committee) for three years for Merck’s CFO setting agendas and chairing meetings discussing HR, talent, Vioxx recall, & other operational issues • Briefed C-Suite and PwC regarding planning, transfer pricing, repatriation, SOX/provision, JVs, audits, & transactions • Established strong relationships with business partners to design novel strategies for acquisitions, licenses, dispositions and JVs that created more than $3B in value and led AJCA cross-functional team to repatriate $15.9B • Devised strategies to resolve IRS audits including settling complex derivative strip & other contentious shelters • Managed tax legislative efforts and represented Merck on PhRMA Tax Committee & industry coalitions

Espoo, Southern Finland, Fi

• Led team that reduced tax rate by six percent. Designed novel supply chain, efficient IP migrations and transfer pricing strategies including Double Irish structure. Supported Caribbean & LATAM including building team to support tax and treasury for Brazil, Europe, Africa & Middle East, and Asia Pac/China operations (rotating over 6 years)• Led more than 50 transactions, JVs, financings, and reorganizations saving billions of dollars in taxes including restructurings in 78 countries associated with Avaya and Agere spin-offs securing rulings for both, including first ever debt/equity exchange enabling $2B in tax-free value extraction. The Daily Deal named Agere “2002 Deal of the Year”• Ran global sale of Optical Fiber Solutions business unit that employed self-developed structures saving $1 billion in taxes. Recognized by Lucent’s Chairman, Henry Schacht, for leading this transaction when M&A head resigned• Led convertible debt offerings and Spinoff IPOs and devised strategies to utilize NOLs and preserve attributes, including $1.9B cash refund claim from $5B loss carry back to AT&T that enabled Lucent to remain solvent

New York, Ny, Us

• Structured and negotiated cutting edge transactions and drafted opinions for leading practice including re: financial products, M&A, transfer pricing, tax credits, tax-exempt entities, foundations, and accounting issues• Supported tax controversies including drafting protests, discovery and pleadings, and selecting and preparing expert witnesses & strategy for the largest transfer pricing case in that era (DHL Corp. v. Commissioner)• Lobbied Congress, Treasury and the IRS regarding tax policy matters

Washington, Dc, Us

• Drafted revenue and private letter rulings for corporate reorganizations and spin-offs

Bachelor Of Business Administration (Bba), Accounting And Finance

Jd, Law

Llm, Taxation

International Business Executive Program Certificate - 2 Week Intensive Case Study Course, “Leadership In The Global Enterprise”

Executive Education Program, “Mastering Capital Markets”